294 reports of this reaction
1.4% of all NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE reports
#17 most reported adverse reaction
DRY MOUTH is the #17 most commonly reported adverse reaction for NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE, manufactured by Nalpropion Pharmaceuticals LLC. There are 294 FDA adverse event reports linking NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE to DRY MOUTH. This represents approximately 1.4% of all 20,475 adverse event reports for this drug.
Patients taking NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE who experience dry mouth should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRY MOUTH is a less commonly reported adverse event for NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to dry mouth, the following adverse reactions have been reported for NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE:
The following drugs have also been linked to dry mouth in FDA adverse event reports:
DRY MOUTH has been reported as an adverse event in 294 FDA reports for NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRY MOUTH accounts for approximately 1.4% of all adverse event reports for NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE, making it a notable side effect.
If you experience dry mouth while taking NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.